DHT Holdings Inc. vs GeneDx Holdings Corp — how do they compare? DHT Holdings Inc. trades at $24.93 (market cap $4.02B), while GeneDx Holdings Corp trades at $67.74 (market cap $2.02B). The key difference: DHT Holdings Inc. is the larger of the two by market cap, and DHT Holdings Inc. pays a 19.57% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold DHT Holdings Inc. for 0 Days and GeneDx Holdings Corp for 19 Days on average.
| DHT | WGS | |
|---|---|---|
Market Cap | $4.02B | $2.02B |
Volume | 5,493,801 | 734,640 |
Sector | Industrials | Health |
52-Week High | $24.93 | $167.51 |
52-Week Low | $11.20 | $34.51 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $4.29B | $2.05B |
Dividend Yield | 19.57% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DHT Holdings operates a fleet of crude oil tankers that trade on international routes. Its fleet consists of very large crude carriers, or VLCCs.
Read more on DHT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →